Introduction {#s1}
============

Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma and represents 30--40% of all non-Hodgkin lymphomas ([@B1]). Based on gene expression profiling, two molecular subtypes of DLBCL, activated B-cell-like (ABC) subtype and germinal center B-cell-like (GCB) subtype, are identified ([@B2], [@B3]). Approximately 60% of patients with DLBCL can be cured by the standard immunochemotherapy regimen rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), but remaining patients are either refractory to induction immunochemotherapy or experience relapses after achieving complete response (CR) ([@B4]--[@B6]). Enormous effort has been devoted to developing new therapeutic approaches for these refractory or relapsed patients, with some success. In rituximab era, using conventional salvage immunochemotherapy with autologous transplant, only \~ 10% of refractory/relapsed DLBCL cases could be cured, whereas the remaining patients have very dismal outcome warranting development of novel therapies ([@B7], [@B8]). Understanding the pathogenesis of DLBCL is vital to define potential therapeutic targets and develop regimens for the treatment of DLBCL ([@B9], [@B10]). As is common to other types of cancer, dysregulation of cell survival or resistance to cell death also contributes to the pathogenesis of DLBCL. DLBCL lymphoma cells have evolved many strategies to resist cell death, which potentially can be therapeutically targeted. In this review, we discuss the mechanisms underlying dysregulation of cell survival in DLBCL and therapeutic options to target related pathways.

Mechanisms Underlying Dysregulation of Cell Survival in Dlbcl {#s2}
=============================================================

B Cell Receptor (BCR) Signaling
-------------------------------

### Normal BCR Signaling

Based on dependence on antigen stimulation, BCR signaling pathways can be categorized into tonic BCR signaling or antigen-dependent BCR signaling. Tonic BCR signaling is vital for maintaining the survival of resting mature B cells, as ablation of cell surface BCR expression or inactivation of BCR result in cell death ([Figure 1](#F1){ref-type="fig"}) ([@B11]). Tonic BCR signaling exerts its pro-survival effects via PI3K signaling, as PI3K signaling can rescue the survival of mature B cells that are deficient in BCR ([@B12]). Activated PI3K/AKT inactivates the pro-apoptotic protein BAD and stabilizes the anti-apoptotic protein MCL1, resulting in enhanced cell survival. Moreover, activated AKT phosphorylates forkhead box class O family member transcription factors (FOXOs) leading to cytosolic retention of FOXOs, impairing FOXOs-mediated transactivation of cell death genes ([@B12]). Antigen-dependent BCR signaling promotes the survival of B cells through activation of a variety of pathways. The binding of antigen causes BCR aggregation, leading to phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) of CD79A and CD79B by SRC kinases, including LYN, FYN, and B lymphocyte kinase (BLK). Phosphorylated ITAMs recruit spleen tyrosine kinase (SYK), which is then phosphorylated and activated by the SRC kinases and autophosphorylation. Activated SYK leads to phosphorylation and activation of the downstream molecules Bruton tyrosine kinase (BTK) and phospholipase Cγ2 (PLCγ2) ([@B9]). PLCγ2 hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3), which results in increased intracellular calcium levels. Increased calcium, in combination with DAG, triggers activation of protein kinase C β (PKCβ) and promotes assembly of the CARD11/BCL10/MALT1 (CBM) complex and NF-κB activation, providing vital pro-survival signals for B cells. In BCR signaling, LYN kinase also leads to the phosphorylation of CD19 thereby promoting recruitment recruitment of PI3K to the BCR, which then activates the PI3K/AKT pathway. Additionally, BCR signaling can also activate the RAS and mitogen-activated protein kinase (MAPK) pathway as well as the transcription factor NFAT, providing additional survival signals for B cells ([@B9]).

![Regulation of B cell receptor (BCR) signaling on B cell survival. Antigen dependent BCR signaling engages several downstream pathways, which include the NF-κB pathway, PI3K/AKT/mTOR pathway, NFAT pathway, and MAPK/ERK pathway. NF-κB activation promotes transcription of the pro-survival genes including BCL2, BFL1, cellular inhibitor of apoptosis protein (cIAP) 1, cIAP2, X-linked inhibitor of apoptosis protein (XIAP) and so on. Additionally, NF-κB antagonizes the function of p53, thereby decreasing p53-mediated cell apoptosis. Activated AKT phosphorylates forkhead box class O family member transcription factors (FOXOs), suppressing the transcription of target genes including pro-apoptosis gene BIM. AKT activation also results in the activation of pro-survival MCL1. Moreover, AKT mediates the phosphorylation of the pro-apoptotic BCL2 family member BAD, and blocks BAD-induced cell apoptosis. The activation of mTOR complex 1 (mTORC1), which suppresses BAD, could be induced by AKT activation or CARD11 activation. Tonic BCR signaling triggers activation of the PI3K/AKT pathway and also promotes cell survival. BTK, Bruton tyrosine kinase; DAG, diacylglycerol; IP3, inositol trisphosphate; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PKCβ, protein kinase C β; PLCλ2, phospholipase λ2; SYK, spleen tyrosine kinase.](fonc-09-00107-g0001){#F1}

### Chronic Active BCR Signaling

ABC DLBCL cells rely on BCR signaling for survival ([@B13]). This type of BCR signaling is dependent on both proximal BCR pathway components and CARD11, similar to that in antigen activated normal B cells, therefore referred as "chronic active" BCR signaling ([@B13]). Down-regulation of chronic active BCR signaling in ABC DLBCL cells leads to inhibition of NF-κB activation as well as phosphorylation of AKT and ERK, dampening pro-survival signaling ([@B13]). Both antigen-dependent BCR activation and genetic aberrations involving the BCR signaling pathway contribute to chronic active BCR signaling activation in ABC DLBCL ([@B13]). One part of the evidence suggesting antigen-dependent BCR activation in ABC DLBCL is remarkable clustering of BCR on the ABC DLBCL cell surface, a characteristic feature of antigen dependent BCR activation in normal B cells ([@B13]). A study by Young et al. showed, in a subset of ABC DLBCL, that binding of self-antigen to BCR drove active BCR signaling and sustained survival of ABC DLBCL cells ([@B14]). Genetic aberrations affecting BCR and downstream signaling contribute to the activation of BCR signaling in ABC DLBCL. A subset of ABC DLBCL cases harbor mutations in the ITAM motif of CD79A (\~3%) and CD79B (\~20%) ([@B13]). Both CD79A and CD79B mutations enhance surface IgM expression, thereby increasing NF-κB activation. *CD79B* mutations also suppress the activity of LYN kinase, impairing LYN kinase mediated negative-feedback inhibition of BCR signaling. Consistently, inactivating *LYN* mutations, and *LYN* deletions have been identified in DLBCL, which possibly enhance activation of BCR signaling. The CARD11/BCL10/MALT1 complex is also affected by activating mutations or amplifications. *CARD11* mutations, which predominantly affect the coil-coil domain, are detected in DLBCL (11--15%) including both ABC and GCB DLBCL ([@B15], [@B16]). These *CARD11* mutations impair the inhibition of domain-mediated auto-inhibition, leading to hyper-activation of CARD11, which subsequently activates the downstream NF-κB pathway ([@B17]). A recent study showed that activated CARD11 could induce the activation of mTOR complex 1 (mTORC1), which provides additional pro-survival signals ([@B18]). With the advent of next-generation sequencing, an increasing number genetic aberrations of BCR regulators have been identified, especially negative BCR regulators, including PTPN6, PRKCD, SLA, LAPTM5, DGKZ, and MAP4K1 ([@B16]). The inactivating mutations or deletions involving these molecules release BCR signaling from inhibition, thus leading to BCR signaling activation.

### Tonic BCR Signaling

Absence of immobile BCR clustering on the cell surface of GCB DLBCL cells suggests lack of chronic active BCR signaling. Moreover, most GCB DLBCLs are relatively insensitive to the BCR inhibitor ibrutinib and do not show activation of NF-κB pathway, further suggesting independence of GCB DLBCL from chronic active BCR signaling ([@B19]). The study by Chen et al. suggested some DLBCL cell lines, which included GCB subtypes, displayed tonic BCR signaling, as these cell lines exhibited detectable SYK and BLNK phosphorylation without BCR crosslinking ([@B20]). Inhibition of SYK dampened tonic BCR signaling and increased cell apoptosis in BCR-dependent DLBCL cell lines, pointing to a role of tonic BCR signaling in sustaining survival of BCR-dependent DLBCL cells ([@B20]). Replacement of BCR antigen-binding regions has no impact on BCR signaling in GCB DLBCL lines, indicating that GCB DLBCL rely on tonic BCR signaling ([@B21]). The biological effect of tonic BCR signaling in GCB DLBCL is highly dependent on AKT activation, as tonic BCR signaling triggers AKT activation and forced AKT activation can rescue GCB DLBCL cells from depletion of the BCR or tonic BCR signaling mediators SYK and CD19 ([@B21]). Genetic aberrations also play a role in promoting tonic BCR signaling. *PTEN* deletions, which are identified in approximately 10% of DLBCL including the GCB and ABC subtypes, can result in enhanced PI3K/AKT signaling ([@B16]). Mir-17-92 targets and negatively regulates expression of PTEN protein, therefore, mir-17-92 amplification, which occurs exclusively in GCB DLBCL (\~8%) ([@B16]), leads to PI3K/AKT activation. These aberrations, by activating PI3K/AKT signaling, lead to increased tonic BCR signaling.

Toll-Like Receptor Signaling and the MyD88--TLR9--BCR Supercomplex
------------------------------------------------------------------

*MYD88*^L265P^ mutation, which involves the adaptor protein MYD88 in the Toll-like receptor (TLR) pathway, is found in approximately 30% of ABC DLBCL, suggesting that abnormal TLR signaling plays a role in the pathogenesis of DLBCL ([@B22]). Physiologically, following recruitment of MYD88 to TLRs, TLR4 forms a complex with interleukin-1 receptor-associated kinase (IRAK) 4, further recruiting other IRAKs (IRAK1 and IRAK2) and causing activation of downstream pathways including the NF-κB pathway ([@B23]). Inhibiting MYD88 using shRNA is toxic to ABC DLBCL cell lines suggesting that MYD88 is essential for the survival of these cell lines ([@B24]). Compared with wild-type MYD88, MYD88^L265P^ leads to enhanced phosphorylation of IRAK, activation of NF-κB, and JAK-STAT3 signaling, and increased secretion of interleukin 6 (IL-6), interleukin 10 (IL-10), and interferon-β promoting the survival of ABC DLBCL cell lines. The study by Avbelj et al. found that MYD88^L265P^ Toll/interleukin-1 receptor (TIR) domain can recruit endogenous wild-type MYD88 to form oligomers, which leads to hyperactivation of downstream pathway ([@B25]). Moreover, conditional expression of *MYD88*^L265P^ mutation in B cells in mice leads to spontaneous development of lymphoproliferative diseases which mimic ABC DLBCL ([@B26]). These data suggest that MYD88^L265P^ activates MYD88, promotes the survival of DLBCL cells, and contributes to the pathogenesis of ABC DLBCL. Additional conditional BCL2 overexpression in this model remarkably accelerates the development of lymphoma ([@B26]). Accordingly, in human DLBCL samples, *BCL2* amplification frequently co-occur with *MYD88*^L265P^ mutations in ABC DLBCL, suggesting the anti-apoptotic function of BCL2 is important for full transformation of B cells by MYD88^L265P^ ([@B27]). This finding also provides a rationale for using BCL2 inhibitors in *MYD88*^L265P^ mutated DLBCL.

Additionally, Co-occurrence of *MYD88*^L265P^ and *CD79B* mutations is frequent in ABC DLBCL, suggesting that these two aberrations might be synergistic in driving ABC DLBCL development ([@B27]). There has been direct evidence that MYD88 and BCR cooperate in the pathogenesis of a subset of DLBCL ([@B28]). A recent study showed that MYD88, TLR9, and the BCR formed a multiprotein supercomplex (MyD88--TLR9--BCR supercomplex, the My-T-BCR supercomplex) in ibrutinib-responsive cell lines and patient samples ([@B28]). The My-T-BCR supercomplex co-localizes with mTOR on endolysosomes to drive NF-κB and mTOR signaling, both of which promote cell survival ([@B28]).

Dysregulation of Apoptosis Molecules
------------------------------------

### Dysregulation of BCL2 Family Members

The BCL2 family consists of a group of proteins that share with Bcl-2 homology (BH) domains ([@B29]). BCL2 family proteins, including anti-apoptotic and pro-apoptotic members, have a crucial role in regulating cell survival by modulating the intrinsic apoptosis pathway. Briefly, signaling including DNA damage and absence of growth factors leads to the activation of BH3-only proteins, which inactivate the pro-survival members such as BCL2, allowing activation of BAX and BAK. BAX and BAK lead to permeabilization of the outer mitochondrial membrane, releasing the pro-apoptotic cytochrome c, which activates caspases. These caspases, via their proteolytic activities, act as the direct mediators of cell apoptosis.

Dysregulation of BCL2 family members has been reported in DLBCL. BCL2, the prototype of this family, is overexpressed in 50%-53% of DLBCL (ABC DLBCL, 53--61%; GCB DLBCL, 40--44%) ([@B30], [@B31]). BCL2 contributes to the pathogenesis of DLBCL by promoting the survival of B cells, as *BCL2*-transgenic mice have B cells with extended survival and these mice spontaneously develop aggressive B cell lymphoma ([@B32]--[@B34]). Several mechanisms contribute to BCL2 overexpression in DLBCL, among which *BCL2* translocation is the most common one. *BCL2* translocation occurs exclusively in GCB DLBCL (\~30%) ([@B16], [@B35], [@B36]), which juxtaposes *BCL2* with the immunoglobulin heavy chain (IGH) enhancer, leading to increased *BCL2* mRNA transcription. *BCL2* copy number alterations, including gains and amplifications, are observed in ABC DLBCL and regarded as contributing factors to BCL2 overexpression ([@B37]). In normal germinal center (GC) B cells, BCL6 binds to the promoter of *BCL2*, and inhibits MIZ1-mediated *BCL2* transcriptional activation ([@B38]). *BCL2* translocations as well as mutations in *BCL2* promoter regions, disrupt BCL6-mediated suppression of *BCL2* transcription, thereby contributing to BCL2 overexpression ([@B38]). MicroRNA (miRNA) dysregulation also contributes to BCL2 overexpression in DLBCL ([@B39]). For instance, miR-34a, which targets BCL2, is down-regulated in DLBCL, contributing to BCL2 overexpression ([@B39]). Mutations in *BCL2* coding sequence (CDS), which is located predominantly in the BH4 and flexible loop domain (FLD), also contribute to the BCL2 dysregulation by affecting the function and stability of BCL2 ([@B40]--[@B42]). The anti-apoptotic BCL2 family member MCL1 is also overexpressed in non-GCB DLBCL (\~50% at protein level), which could be caused by *MCL1* gains or amplification or abnormal activated STAT3 signaling ([@B43]). MCL1 possibly contributes to the pathogenesis of DLBCL by promoting cell survival, as *MCL1* transgenic mice spontaneously develop DLBCL and inhibition of MCL1 in DLBCL cell lines induces cell death ([@B43], [@B44]). Another BCL2 family anti-apoptotic member, BCL-w, has been shown to be overexpressed in \~90% of DLBCL (60% with high expression) and BCL-w overexpression was associated with poor prognosis ([@B45], [@B46]). The RNA level of BCL-w is inversely correlated with that of BCL2 in DLBCL samples, pointing to a possible complementary role of BCL-w to BCL2 in the pathogenesis of DLBCL ([@B46]). Loss of BCL-w sensitized B cell to growth factor deprivation-induced cell apoptosis and suppressed MYC-induced lymphomagenesis, suggesting a crucial role of BCL-w in B cell survival and lymphoma development ([@B45]). Nevertheless, the mechanisms underlying BCL-w overexpression in DLBCL remain not well-defined. In summary, abnormalities in anti-apoptotic members of the BCL2 family, such as BCL2, MCL1, and BCL-w, lead to enhanced B cell survival and contribute to DLBCL development.

### Dysregulation of Inhibitor of Apoptosis Proteins

Inhibitor of apoptosis proteins (IAPs) inhibit cell apoptosis by binding specific caspases. Dysregulation of IAPs has been reported in DLBCL. Cellular inhibitor of apoptosis protein 1 (cIAP1), cellular inhibitor of apoptosis protein 2 (cIAP2), and X-linked inhibitor of apoptosis protein (XIAP) are reported in 92, 37, and 26\~55% of DLBCL, respectively ([@B47], [@B48]). And the overexpression of XIAP in DLBCL is significantly associated with worse outcome ([@B48]). Pharmacological inhibition of XIAP induces cell apoptosis in DLBCL cell lines, supporting the role of XIAP in maintaining cell survival of DLBCL cells ([@B48]). Survivin, another member of the inhibitor of apoptosis protein family, has been found to be overexpressed in \~60% of DLBCL ([@B49]). And in ABC DLBCL, survivin overexpression significantly predicted worse outcome ([@B49]). These pieces of evidence suggest that survivin has a pathogenic role in DLBCL.

### TP53 Dysregulation

The p53 transcription factor has a crucial role in regulating cell survival. Under normal conditions, the E3 ligase MDM2 targets p53 for degradation in a negative feedback manner, thus maintaining a low expression level of p53. Additionally, MDM2 suppresses p53 mediated transcriptional activation and promotes the transportation from the nucleus to the cytoplasm ([@B50], [@B51]). Cellular stresses, including DNA damage, can disrupt the binding of MDM2 to p53 and increase p53 protein expression. P53 activates transcription of several genes that are involved in cell apoptosis, including BAX, PUMA, and NOXA ([Figure 2](#F2){ref-type="fig"}). TP53 dysfunction is common in DLBCL ([@B52]) and restoration of p53 expression tumor cell induces apoptosis in an Eμ-*Myc* mouse model, suggesting a role of p53 dysregulation in DLBCL development ([@B53]). P53 dysregulation also contributes to chemoresistance in DLBCL, as p53 functions as an important mediator of chemotherapy induced cell death. Clinically, *TP53* mutation is an independent prognostic factor of poor outcome in DLBCL patients treated with R-CHOP chemotherapy ([@B54]).

![Genetic aberrations causing p53 dysfunction leads to dysregulated cell survival. Mutations involving the coding DNA sequence region of the *TP53* gene affect the protein structure and abrogate p53 tumor suppressor function. Other aberrations lead to decreased p53 translation or stability or altered protein modification. MDM2 and MDM4 also inhibit p53-mediated transcription activation. Decreased p53 nuclear accumulation caused by MDM2 amplifications or KDM6B deletions leads to p53 dysfunction. Impaired p53 function leads to decreased transcription of pro-apoptotic genes, resulting in abnormally enhanced cell survival.](fonc-09-00107-g0002){#F2}

Many different mechanisms contribute to p53 dysregulation in DLBCL. Among these mechanisms, *TP53* mutation is the most common one, occurring in \~20% of all DLBCL cases ([@B16], [@B52]). *TP53* mutations in the CDS regions mostly target exons 4 through 9, frequently involving the DNA binding domain and impairing p53 mediated transcriptional transactivation ([@B52]). Heterogeneous or homogeneous *TP53* deletions that lead to decreased *TP53* gene dosage occur in \~ 10% of DLBCL cases ([@B52], [@B55]). BCL6, which is frequently dyregulated in DLBCL, binds to the *TP53* promoter region and suppresses the transcription of *TP53* gene ([@B56]). *MDM2* is amplified in a subset of DLBCL, contributing to increased ubiquitylation and degradation of p53 as well as decreased nuclear accumulation and transcriptional activity ([@B57]). MDM4, a protein that shares structural similarity with MDM2, inhibits p53 transcriptional activity. Amplifications of *MDM4* are also detected in DLBCL, possibly decreasing transcriptional activity of p53 ([@B57]). *ARF*, which encodes a protein that promotes MDM2 degradation and stabilizes p53, is frequently deleted in DLBCL, as a part of the *CDKN2A* locus ([@B55], [@B58]). *ARF* deletion contributes to the pathogenesis of DLBCL, at least partly via decreasing p53 protein level. Deletions of *KDM6B* and *RPL26*, which are located with *TP53* in the 17p13.1 region, are recurrent in DLBCL ([@B57]). Under normal conditions, the demethylase KDM6B can activate *ARF* transcription by demethylating the *p14ARF* locus ([@B59]). Additionally, KDM6B directly interacts with p53 by demethylating p53 and causes accumulation of p53 in the nucleus, thereby activating the function of p53 ([@B60]). Therefore, loss of *KDM6B* might decrease *ARF* transcription and p53 stability and p53 nuclear accumulation, thereby leading to p53 dysregulation.

RPL26 can bind the 5′ UTR of *TP53* and facilitate p53 translation, which increases stress-induced p53 expression ([@B61]). Thus, lack of RPL26 may decrease p53 expression by impeding p53 translation. Several other genetic aberrations may attenuate p53 protein function. ATM, which phosphorylates and activates p53, is recurrently mutated in DLBCL and may lead to impaired activation of p53 ([@B16]). Both CREBBP and EP300 can acetylate p53 and activate p53 transcriptional activity ([@B62]). Mutations in CREBBP and EP300 occur in DLBCL inactivating the acetyltransferase activity of these two proteins, thereby impairing p53 acetylation and activity ([@B63]).

Tumor Microenvironment (TME) Dysfunction
----------------------------------------

The TME consists of vasculature, immune cells, fibroblasts, signaling molecules, and the extracellular matrix. In contrast with low-grade B cell lymphomas, DLBCL is relatively less dependent on the TME. Nevertheless, there is evidence suggesting that the TME provides indispensable survival signals in at least some cases of DLBCL. Not all DLBCL cells can be cultured *in vitro*, suggesting that these cells might be dependent on the TME to survive ([@B64]). Furthermore, in clinical settings the presence of certain types of immune cells predicts a poorer prognosis in DLBCL patients, suggesting that these immune cells might support the survival of DLBCL tumor cells or mediate lymphoma cell drug-resistance ([@B65]--[@B68]). Immune escape definitely contributes to the survival of DLBCL cells, however, this is not the focus of our review. Here, we discuss how the TME provides pro-survival signals to tumor cells. Several types of cells in the TME can provide survival signals for DLBCL cells ([Figure 3](#F3){ref-type="fig"}).

![Survival signals from the tumor microenvironment. Immune cells and stromal cells promote tumor cell survival through cell-to-cell contact and secreting pro-survival factors. Several types of cells in the tumor microenvironment secret pro-survival factors including B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), hedgehog (Hh) ligands, and interleukin-10 (IL-10). These factors bind to corresponding receptors on the tumor cell surface, providing important pro-survival signals to the tumor cells. Neutrophils form neutrophil extracellular traps (NETs), which activate Toll-like receptor 9 (TLR9) pathway to promote survival of diffuse large B cell tumor cells. CXCL8, C-X-C motif chemokine ligand 8; IL-8, interleukin-8.](fonc-09-00107-g0003){#F3}

### Neutrophils

Coculture of neutrophils with DLBCL cell lines can sustain the survival of DLBCL cell lines ([@B69]). This effect is associated with decreased DLBCL cell apoptosis, suggesting that neutrophils promote the survival of DLBCL cells ([@B69]). In DLBCL, tumor-infiltrating neutrophils can secrete a proliferation-inducing ligand (APRIL) and cause overexpression of APRIL in DLBCL tissues, which could be related to poorer outcome of DLBCL patients ([@B70]). APRIL, which is a ligand of tumor necrosis factor (TNF) superfamily, can bind to B cell maturation antigen (BCMA) and the transmembrane activator and calcium modulator cyclophilin ligand interactor (TACI) and has a crucial role in regulating B cell survival ([@B71]). Mechanistically, DLBCL can produce C-X-C motif chemokine ligand 8 (CXCL8), which can recruit neutrophils expressing APRIL, thereby providing the tumor cells with pro-survival signals ([@B72]). Additionally, DLBCL derived interleukin-8 (IL-8) can induce neutrophils to form neutrophil extracellular traps (NETs) by binding to its receptor CXCR2 on neutrophils. The formed NETs directly activates TLR9 pathways in DLBCL, leading up-regulation of NF-κB, STAT3 and p38 pathways, which provide pro-survival signals ([@B73]).

### Stromal Cells

Bone marrow stromal cells protect DLBCL cell lines and primary DLBCL cells through a combination of soluble factors and cell-to-cell contact. When co-cultured with mouse bone marrow stromal cells, primary human DLBCL cells have significantly increased clonogenicity and tumorigenicity ([@B74]). Bone marrow stromal cells secret B-cell activating factor (BAFF) and promote survival and drug-resistance of DLBCL cell lines. The adhesion of bone marrow stromal cells to DLBCL cells also can lead to activation of NF-κB pathway, which further up-regulates anti-apoptotic proteins c-IAPs and XIAP, leading to improved survival of lymphoma cells ([@B75]). These data suggest that bone marrow stromal cells have an important role in enhancing the survival of DLBCL tumor cells in the bone marrow microenvironment. Additionally, stromal cells can express hedgehog ligands and activate hedgehog signaling in B cell malignancies including DLBCL, promoting survival of these lymphoma cells ([@B76]). Co-culture of DLBCL cells with stromal cells results in up-regulation of BCL2, BCL-xL, and BCL2A1, which enhance cell survival ([@B77]). Inhibition of hedgehog signaling triggers apoptosis via down-regulating BCL2, suggesting the pro-survival effect provided by stromal cells is mediated, at least partly, by up-regulation of BCL2 ([@B76]). Stromal cells induced hedgehog signaling also contribute to chemoresistance by activating the transcription of adenosine triphosphate-binding cassette drug transporter ABCG2, thereby preventing DLBCL cells from cell death caused by chemotherapy ([@B77]). In addition to directly supporting the survival of DLBCL cells, stromal cells also recruits monocytes and neutrophils, which can provide additional pro-survival signals ([@B73]).

### Other Types of Cells

Expansion of CD14 (+) CD169 (--) monocyte-derived cells that have dendritic cell differentiation potential is frequent in DLBCL ([@B78]). Coculture of monocytes with DLBCL cells can prolong the survival of the lymphoma cells ([@B79]). The mechanisms underlying monocyte support for DLBCL survival are less clear, and the effects are not mediated by BAFF, suggesting other factors may play a role ([@B79]). It is known that follicular helper T (Tfh) cells have a crucial role in the development of B cells. It remains to be determined if Tfh cells in the TME have a role in promoting the survival of DLBCL lymphoma cells. It has been shown that circulating CXCR5^+^CD4^+^ T cells enhance the survival of primary DLBCL cells through IL-10, indicating that these T cells may have a similar role in the TME ([@B80]).

These studies, in combination, support a role for the TME in enhancing DLBCL cell survival.

Epstein-Barr Virus (EBV) Infection
----------------------------------

EBV infects B cells in most human hosts and is related to several types of B cell lymphoma. EBV-positive DLBCL, not otherwise specified, which accounts for \~ 10% of DLBCL ([@B81]), has been recognized as a distinct lymphoma entity. This disease usually occurs in individuals aged \>50 years but can also occur in younger patients ([@B82]). Although elderly patients have an unfavorable outcome, the prognosis of young patients is excellent ([@B82]). By regulating different pathways, EBV promotes the survival of B cells and is implicated in DLBCL pathogenesis. EBV nuclear antigen 2 (EBNA2) and latent membrane protein 1 (LMP1) are expressed in 7--36% and over 90% of EBV^+^ DLBCL cases, respectively, suggesting type III and more frequently type II EBV latency ([@B82]). It is recognized that LMP1 is indispensable for prolonging the survival of transformed B cells ([@B83]). By mimicking the TNF-receptor superfamily member CD40, LMP1 activates the NF-κB pathway and several other pathways to promote cell proliferation and survival in transformed B cells ([@B84], [@B85]) ([Figure 4](#F4){ref-type="fig"}). The cytoplasmic c-terminal tail of LMP1 has two effector domains, C-terminal activation regions 1 and 2 (CTAR1 and 2), which are essential for downstream NF-κB activation ([@B85]). CTAR1 recruits and interacts with TNF receptor associated factor (TRAF) members, thus activating downstream NF-κB, PI3K/AKT, p38 MAPK, and the ERK/MAPK pathway ([@B86]--[@B88]). CTAR2 recruits TNF receptor-associated death domain proteins to activate downstream pathways, including NF-κB, JNK, and the ERK/MAPK pathway ([@B85], [@B87]). Another effector domain, CTAR3, is located between CTAR1 and CTAR2 and can interact with JAK3 and activate the JAK/STAT pathway ([@B89]). Additionally, LMP1 induces BCL2 expression in infected B cells and prevents these cells from undergoing apoptosis ([@B90]). Accordingly, BCL2 is virtually always positive in EBV^+^ DLBCL ([@B91]). LMP1 down-regulates the expression of a sphingosine-1-phosphate (S1P) receptor S1PR2 at the transcriptional level, a molecule that inhibits PI3K/AKT pathway, contributing to PI3K/AKT pathway activation ([@B92]). EBNA2 also up-regulates the anti-apoptotic protein BFL1 ([@B93]). Some EBV miRNAs improve the survival of B cells by targeting pro-apoptotic proteins. For example, EBV-miR-Bam HI A region rightward transcript (BART)-cluster 1 and 2 and EBV-miR-BART5 target the pro-apoptotic proteins BIM and PUMA, respectively, thereby increasing the survival of infected B cells ([@B94], [@B95]).

![Epstein-Barr virus (EBV) contributes to dysregulation of survival of diffuse large B cell lymphoma (DLBCL) cells. In EBV positive DLBCL, LMP1, EBV nuclear antigen 2 (EBNA2), and several EBV microRNAs could lead to abnormal survival of DLBCL cells, contributing to the pathogenesis of EBV positive DLBCL. These factors lead to enhanced survival of DLBCL cells by increasing pro-survival signals or suppressing pro-apoptotic proteins. Abbreviations: BART, Bam HI A region rightward transcript; CTAR, C-terminal activation region; TRADD, tumor necrosis factor receptor type 1--associated death domain; TRAF, tumor necrosis factor receptor associated factor.](fonc-09-00107-g0004){#F4}

Therapeutic Strategies {#s3}
======================

An increasing number of novel drugs targeting aberrant cell survival through modulating different pathways have shown efficacy in preclinical studies and/or clinical trials, with some of these drugs showing moderate or significant activities ([@B1], [@B96]). These drugs targeting different pathways are summarized in [Table 1](#T1){ref-type="table"}. Ongoing trials testing some of these drugs in DLBCL have been summarized in [Table 2](#T2){ref-type="table"}.

###### 

Selected drugs targeting aberrant cell survival in diffuse B cell lymphoma.

  **Pathways**      **Targets**   **Drugs**
  ----------------- ------------- ------------------------------------------------------------------------------
  BCR signaling     BTK           Ibrutinib, BGB-3111, acalabrutinib, TG-1701
                    MALT1         Phenothiazines, MI-2
                    PKC-β         Enzastaurin
                    SYK           Fostamatinib, entospletinib, TAK-659
                    PI3K          Copanlisib, buparlisib, CUDC-907, idelalisib, YY-20394, INCB050465, TGR-1202
                    AKT           AZD5363, MK2206
                    mTOR          Everolimus, temsirolimus
  BCL2 family       BCL2          Navitoclax, venetoclax, obatoclax
                    MCL1          S63845, AMG176
  The p53 pathway   p53           APR-246
                    MDM2          Nutlin-3a, idasanutlin
                    MDM4          XI-011
                    XPO1          Selinexor

*BTK, Bruton tyrosine kinase; PKCβ, Protein kinase C β; SYK, spleen tyrosine kinase*.

###### 

Ongoing trials with drugs targeting cell survival in diffuse large B cell lymphoma.

  **Target**    **Drug**                   **NCT number**   **Phase**   **Indication[^a^](#TN1){ref-type="table-fn"}**                                           **Treatments[^b^](#TN2){ref-type="table-fn"}**
  ------------- -------------------------- ---------------- ----------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  BTK           Ibrutinib                  NCT02733042      I/II        R/R lymphoma or CLL                                                                      Durvalumab + lenalidomide ± R; Durvalumab+ibrutinib; Durvalumab + bendamustine ± R; Durvalumab monotherapy
  BTK           Ibrutinib                  NCT01479842      I           R/R DLBCL, MCL, or indolent NHL                                                          R + bendamustine + ibrutinib
  BTK           Ibrutinib                  NCT02436707      II          R/R aggressive B-cell lymphoma                                                           R-GDP; Ibrutinib+R-GDP; R + cisplatin + mesna + cyclophosphamide + etoposide + G-CSF
  BTK           Ibrutinib                  NCT02950220      I           R/R NHL                                                                                  Ibrutinib + pembrolizumab
  BTK           Ibrutinib                  NCT02747732      II          R/R aggressive B cell lymphoma                                                           Ibrutinib + bendamustine + R
  BTK           Ibrutinib                  NCT01109069      II          R/R B cell Lymphoma                                                                      Ibrutinib
  BTK           Ibrutinib                  NCT03479268      I           R/R CLL or NHL                                                                           Ibrutinib + pevonedistat
  BTK           Ibrutinib                  NCT01955499      I           R/R B-cell NHL                                                                           Ibrutinib + lenalidomide
  BTK           Ibrutinib                  NCT02955628      II          Transplant-eligible R/R DLBCL                                                            Ibrutinib + RICE
  BTK           Ibrutinib                  NCT03770416      II          R/R central nervous system lymphoma                                                      Ibrutinib + nivolumab
  BTK           Ibrutinib                  NCT02401048      I/II        R/R DLBCL or FL                                                                          Ibrutinib + MEDI4736
  BTK           Ibrutinib                  NCT02077166      I/II        R DLBCL                                                                                  Ibrutinib + lenalidomide + R
  BTK           Ibrutinib                  NCT02203526      I           PCNSL                                                                                    Ibrutinib followed by DA-TEDDI-R
  BTK           Ibrutinib                  NCT02692248      II          R/R non-GCB DLBCL (non-candidates for ASCT)                                              Ibrutinib + R + gemcitabine + oxaliplatin + dexamethasone followed by ibrutinib
  BTK           Ibrutinib                  NCT02315326      I/II        R/R PCNSL and SCNSL                                                                      Ibrutinib; ibrutinib + HD-MTX; ibrutinib + R + HD-MTX
  BTK           Ibrutinib                  NCT03703167      I           R/R PCNSL and SCNSL                                                                      Ibrutinib + R + lenalidomide
  BTK           Ibrutinib                  NCT02760485      I/II        R/R DLBCL                                                                                Ibrutinib + itacitinib
  BTK           Ibrutinib                  NCT02703272      III         Pediatric and young adult patients with R/R mature B-cell NHL                            Ibrutinib + RICE/RVICI; RICE/RVICI
  BTK           Ibrutinib                  NCT03684694      I           R/R DLBCL or MCL                                                                         Ibrutinib + loncastuximab tesirine
  BTK           Ibrutinib                  NCT02542514      II          R/R PCNSL or intraocular Lymphoma                                                        Ibrutinib
  BTK           Ibrutinib                  NCT03220022      I           HIV-positive stage II-IV DLBCL                                                           Ibrutinib + R-DA-EPOCH
  BTK           Ibrutinib                  NCT03129828      I/II        Elderly patients With CD20^+^ DLBCL, IPI ≥ 2                                             Ibrutinib + bortezomib + R-CHOP
  BTK           Ibrutinib                  NCT01855750      III         Newly diagnosed non-GCB DLBCL                                                            Ibrutinib + R-CHOP vs. placebo + R-CHOP
  BTK           Ibrutinib                  NCT02670616      II          Newly diagnosed Epstein-Barr virus-positive DLBCL                                        Ibrutinib + R-CHOP
  BTK           Ibrutinib                  NCT03399513      II          Untreated younger, high-risk patients with DLBCL                                         Ibrutinib and R-CHOEP-14
  BTK           Ibrutinib                  NCT02636322      II          Untreated high risk DLBCL                                                                Lenalidomide + ibrutinib + R-DA-EPOCH; Lenalidomide + ibrutinib + R-CHOP
  BTK           Ibrutinib                  NCT02623010      II          Newly diagnosed PCNSL                                                                    Ibrutinib maintenance
  BTK           BGB-3111                   NCT02795182      I           R/R B cell malignancies                                                                  BGB-3111 + BGB-A317
  BTK           BGB-3111                   NCT03145064      II          R/R non-GCB DLBCL                                                                        BGB-3111
  BTK           BGB-3111                   NCT02343120      I           R/R B cell lymphoma                                                                      BGB-3111
  BTK           BGB-3111                   NCT03189524      I           R/R B cell lymphoma                                                                      BGB-3111
  BTK           Acalabrutinib              NCT02362035      Ib/II       R/R hematologic malignancies                                                             Acalabrutinib + pembrolizumab
  BTK           Acalabrutinib              NCT03736616      II          R/R DLBCL                                                                                Acalabrutinib + RICE
  BTK           Acalabrutinib              NCT03571308      Ib/II       Untreated DLBCL                                                                          Acalabrutinib + R-CHOP
  PKC-β         Enzastaurin                NCT03263026      III         Untreated DLBCL with genomic biomarker DGM1™                                             Enzastaurin + R-CHOP vs. R-CHOP
  SYK           entospletinib              NCT03225924      I/II        Newly diagnosed DLBCL (aaIPI ≥ 1)                                                        Entospletinib+R-CHOP vs. R-CHOP
  SYK           TAK-659                    NCT02954406      I           R/R advanced NHL                                                                         TAK-659 + bendamustine; TAK-659 + bendamustine + R; TAK-659 + gemcitabine; TAK-659 + lenalidomide; TAK-659 + ibrutinib
  SYK           TAK-659                    NCT02000934      I           Advanced solid tumor and R/R lymphoma                                                    TAK-659
  SYK           TAK-659                    NCT03238651      I           R/R NHL                                                                                  TAK-659
  SYK           TAK-659                    NCT03123393      II          R/R DLBCL                                                                                TAK-659
  SYK           TAK-659                    NCT03772288      I           R/R advanced NHL                                                                         TAK-659 + NKTR-214
  SYK           TAK-659                    NCT03742258      I           Newly diagnosed high-risk DLBCL                                                          TAK-659 + R-CHOP
  PI3K          Copanlisib                 NCT01660451      II          R/R indolent or aggressive NHL                                                           Copanlisib
  PI3K          Copanlisib                 NCT03484819      II          R/R DLBCL and PMBCL                                                                      Copanlisib + nivolumab
  PI3K          Copanlisib                 NCT03502733      I           Metastatic solid tumors or lymphoma                                                      Copanlisib + nivolumab
  PI3K          CUDC-907                   NCT02909777      I           R/R solid tumors, CNS tumors, or lymphoma                                                CUDC-907
  PI3K          CUDC-907                   NCT02674750      II          R/R DLBCL                                                                                CUDC-907
  PI3K          Idelalisib                 NCT03151057      I           Post allogeneic HSCT in B cell malignancies                                              Idelalisib
  PI3K          Idelalisib                 NCT03576443      II          R/R DLBCL                                                                                Idelalisib
  PI3K          TGR-1202                   NCT01767766      I           R/R hematological malignancies                                                           TGR-1202
  PI3K          TGR-1202                   NCT02006485      I           R/R B cell malignancies                                                                  TGR-1202 + ublituximab; TGR-1202 + ublituximab + ibrutinib; TGR-1202 + ublituximab + bendamustine
  PI3K          TGR-1202                   NCT02793583      IIb         R/R NHL                                                                                  TGR-1202 + ublituximab; TGR-1202; TGR-1202 + ublituximab + bendamustine
  PI3K          TGR-1202                   NCT03283137      I           R/R CLL and B cell NHL                                                                   TGR-1202+ pembrolizumab
  PI3K          TGR-1202                   NCT02867618      I/II        R/R lymphoma                                                                             TGR-1202+ carfilzomib
  PI3K          YY-20394                   NCT03757000      I           R/R B cell malignancies                                                                  YY-20394
  PI3K          INCB050465                 NCT03424122      I           R/R B cell lymphoma                                                                      INCB050465 + R; INCB050465 + bendamustine + R; INCB050465 + ibrutinib
  mTOR          Everolimus                 NCT01075321      I/II        R/R NHL                                                                                  Everolimus + lenalidomide
  mTOR          Everolimus                 NCT00918333      I/II        R/R MM, NHL or HL                                                                        Everolimus + panobinostat
  mTOR          Everolimus                 NCT01665768      II          After high-dose consolidative therapy in lymphoma                                        Maintenance: everolimus + R
  mTOR          Everolimus                 NCT00474929      I/II        R/R lymphoma or MM                                                                       Everolimus + sorafenib
  mTOR          Everolimus                 NCT00436618      II          R/R lymphoma                                                                             Everolimus
  mTOR          Temsirolimus               NCT01076543      I/II        R/R HL or NHL                                                                            Temsirolimus and lenalidomide
  BCL2          Venetoclax                 NCT03236857      I           Pediatric and young adult patients With R/R malignancies                                 Venetoclax ± chemotherapy
  BCL2          Venetoclax                 NCT02265731      I/II        R/R hematologic malignancies                                                             Venetoclax
  BCL2          Venetoclax                 NCT03797261      I           R/R hematologic malignancies                                                             Venetoclax + AMG 176
  BCL2          Venetoclax                 NCT03583424      I/II        R/R NHL                                                                                  Venetoclax + BEAM conditioning for ASCT
  BCL2          Venetoclax                 NCT02992522      I           R/R B-cell NHL                                                                           Venetoclax + obinutuzumab + lenalidomide
  BCL2          Venetoclax                 NCT03082209      I           R/R solid tumors and hematologic malignancies                                            Venetoclax + ABBV-621
  BCL2          Venetoclax                 NCT02391480      I           R/R cancer                                                                               ABBV-075; venetoclax + ABBV-075
  BCL2          Venetoclax                 NCT01328626      I           R/R CLL or NHL                                                                           Venetoclax
  BCL2          Venetoclax                 NCT02987400      II          R/R DLBCL                                                                                Venetoclax + obinutuzumab
  BCL2          Venetoclax                 NCT02611323      I           R/R FL or DLBCL                                                                          Venetoclax + R + polatuzumab vedotin
  BCL2          Venetoclax                 NCT01594229      I           R/R NHL                                                                                  Venetoclax + bendamustine + R
  BCL2          Venetoclax                 NCT03276468      I           R/R lymphoma                                                                             Venetoclax + atezolizumab + obinutuzumab
  BCL2          Venetoclax                 NCT03255096      I           R/R DLBCL and/or HGBL and/or HGBL with MYC and/or BCL2 and/or BCL6 gene rearrangements   Venetoclax + RO6870810 ± R
  BCL2          Venetoclax                 NCT03064867      I           R/R DLBCL                                                                                Venetoclax plus R-ICE
  BCL2          Venetoclax                 NCT03713580      I           R/R NHL (eligible for ASCT)                                                              Venetoclax + BEAM conditioning regimen
  BCL2          Venetoclax                 NCT03036904      I           Untreated aggressive B-cell lymphoma                                                     Venetoclax+ R-DA-EPOCH
  BCL2          Venetoclax                 NCT02055820      Ib/II       Untreated DLBCL                                                                          Venetoclax + CHOP + obinutuzumab or rituximab
  MDM2          Idasanutlin                NCT02624986      Ib/II       R/R DLBCL or FL                                                                          Idasanutlin + obinutuzumab or R
  XPO1          Selinexor                  NCT02323880      I           Younger R/R solid tumors or high-grade gliomas                                           Selinexor
  XPO1          Selinexor                  NCT02471911      I           R/R aggressive B cell lymphoma                                                           Selinexor + RICE
  XPO1          Selinexor                  NCT02741388      I           R/R B cell lymphoma                                                                      Selinexor + R-DHAOx; selinexor + R-GDP
  XPO1          Selinexor                  NCT03147885      Ib/II       Newly diagnosed B cell NHL                                                               Selinexor + R-CHOP
  BTK + BCL2    Ibrutinib + venetoclax     NCT03223610      I           R/R B cell lymphoma                                                                      Ibrutinib + venetoclax + prednisone + obinutuzumab + lenalidomide
  BTK + BCL2    Ibrutinib + venetoclax     NCT03136497      I           R/R DLBCL                                                                                Ibrutinib + venetoclax + R
  BTK+PI3K      TG-1701 + TGR-1202         NCT03671590      I           R/R NHL or CLL                                                                           TG-1701 + TGR-1202 + ublituximab
  BTK+PI3K      Ibrutinib + buparlisib     NCT02756247      I           R/R MCL, FL and DLBCL                                                                    Ibrutinib + buparlisib
  BTK+PI3K      Ibrutinib + TGR-1202       NCT02874404      II          R/R DLBCL                                                                                Ibrutinib + TGR-1202
  BTK+PI3K      Ibrutinib + copanlisib     NCT03581942      IB/II       R/R PCNSL                                                                                Ibrutinib + copanlisib
  SYK+BCL2      TAK-659 + venetoclax       NCT03357627      I           R/R NHL                                                                                  TAK-659 + venetoclax
  BTK+XPO1      Ibrutinib + selinexor      NCT02303392      I           R/R CLL or aggressive NHL                                                                Ibrutinib + selinexor
  BCL2 + MDM2   Venetoclax + idasanutlin   NCT03135262      Ib/II       R/R DLBCL or FL                                                                          Venetoclax + idasanutlin + obinutuzumab or R

*These ongoing clinical trials are for diffuse large B cell lymphoma or include diffuse large B cell lymphoma as well as other types of tumors*;

*This column described treatments for diffuse large B cell lymphoma*.

*aaIPI, age-adjusted international prognostic index; ABC, activated B-cell; ASCT, autologous stem cell transplant; BEAM, carmustine, etoposide, cytarabine and melphalan; BTK, Bruton tyrosine kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL, chronic lymphocytic leukemia; CNS, central nervous system; DA-TEDDI-R, temozolomide, etoposide, liposomal doxorubicin, dexamethasone, ibrutinib and rituximab; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; GCB, germinal center B-cell; G-CSF, granulocyte-colony stimulating factor; HD-MTX, high-dose methotrexate; HGBL, high-grade B cell lymphoma; HL, Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; IPI, international prognostic index; MCL, mantle cell lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma; PMBCL, primary mediastinal large B-Cell lymphoma; R, rituximab; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOEP-14, rituximab plus cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone every 2 weeks; R-DA-EPOCH, rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; R-DHAOx, rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin; R-GDP, rituximab, gemcitabine, cisplatin, and dexamethasone; RICE, rituximab, ifosfamide, carboplatin, and etoposide; R/R, relapsed or refractory; RVICI, rituximab, vincristine, ifosfamide, carboplatin, and idarubicin; SCNSL, secondary central nervous system lymphoma*.

Targeting the BCR Pathway
-------------------------

The BCR pathway has emerged as a crucial target for treating DLBCL patients. Several inhibitors that target molecules in the BCR signaling pathway have shown efficacy in preclinical studies and/or clinical trials. BTK is an important target for suppressing BCR signaling and inhibiting BTK impairs the survival of ABC DLBCL cell lines. The BTK inhibitor ibrutinib has shown significant efficacy in relapsed/refractory ABC-DLBCL patients, especially in those tumors with concurrent *MYD88*^L265P^ and *CD79B* mutations ([@B97]). The combination of ibrutinib with immunochemotherapy has achieved promising responses in newly-diagnosed DLBCL or refractory/relapsed DLBCL patients ([@B98], [@B99]). Other BTK inhibitors, including BGB-3111 and acalabrutinib, are now being tested in DLBCL. MALT1, which acts as an adaptor protein to activate the downstream NF-kB pathway, has emerged as a potential therapeutic target ([@B100]). Several small molecule MALT1 inhibitors, which inhibit the protease activity of MALT1, have shown remarkable anti-tumor effects on ABC DLBCL cells *in vitro* and *in vivo* ([@B101], [@B102]). As a key signaling hub downstream of BCR signaling, PKC-β has been an attractive target for treating DLBCL and the PKC-β inhibitor enzastaurin has been tested in refractory/relapsed or newly-diagnosed DLBCL patients. For refractory/relapsed DLBCL, only a small proportion of patients responded to single agent enzastaurin ([@B103]). Additionally, incorporating enzastaurin into induction chemotherapy in newly diagnosed DLBCL patients or using enzastaurin as maintenance after CR in high-risk DLBCL did not provide significant survival benefits ([@B104], [@B105]). SYK dependent tonic BCR signaling is indispensable for the survival of DLBCL cell lines, which provides a rationale for targeting SYK in the treatment of DLBCL ([@B20]). The selective SYK inhibitor fostamatinib has shown significant activity in refractory/relapsed DLBCL, with 5 of 23 patients achieving a response in a phase 1/2 study ([@B106]). Nonetheless, a phase 2 study including 68 refractory/relapsed DLBCL patients showed that only 3% of patients achieved a response ([@B107]).

The PI3K/AKT pathway is involved in the downstream of both chronic and tonic BCR signaling. Therefore, inhibiting PI3K/AKT pathway can be used as a strategy to suppress cell survival in both ABC DLBCL and GCB DLBCL. In ABC-DBCL cell lines with *CD79B* mutations, PI3K inhibition decreases NF-κB activity and impairs the survival of affected DLBCL cell lines ([@B108]). Additionally, in GCB DLBCL cell lines, pharmacologic PI3K inhibition selectively impairs survival of PTEN-deficient cell lines ([@B109]). A pan-class I PI3k inhibitor, copanlisib, has been tested in refractory/relapsed DLBCL patients as a single agent in phase 1 and 2 clinical trials ([@B110], [@B111]). In the phase 2 trial, the overall response rate (ORR) was 25% (10 of 40) with 5 CRs. The ORR was 13.6% with 1 CR in GCB-type patients and 37.5% with 4 CRs (25%) in ABC-type patients, suggesting that ABC-type had a better response to copanlisib ([@B111]). In an expanded phase 1 trial of CUDC-907, a dual inhibitor of histone deacetylase (HDAC) and PI3K, 11 of 30 evaluable patients had an objective response including 5 CR ([@B112]). AKT inhibitors showed activities in DLBCL in preclinical studies as well ([@B113]--[@B115]). The AKT inhibitor AZD5363 was effective in PTEN-deficient DLBCL irrespective of cell-of-origin subtype ([@B115]). Another AKT inhibitor, MK2206, also showed significant activity in preclinical DLBCL models, however, in a phase 2 trial, none of 9 evaluable patients treated with MK2206 had a response ([@B116]). Activation of PI3K/AKT contributes to activation of mTOR signaling, which promotes the survival of DLBCLs. In addition to PI3K/AKT activation, mTOR could also be driven by activated CARD11 or the My-T-BCR supercomplex ([@B28]). Inhibition of mTOR also could be a strategy to suppress the survival of DLBCL cells. The mTOR inhibitors everolimus and temsirolimus have shown significant single-agent activity in refractory/relapsed DLBCL patients, providing additional salvage therapeutic options ([@B117], [@B118]). Given the pathogenic role of the My-T-BCR supercomplex, combination of mTOR inhibitors with BCR inhibitors could be used in DLBCL depending on the My-T-BCR supercomplex ([@B28]), and BTK inhibitor ibrutinib and mTOR inhibitor are synergistic in suppressing the growth the xenografts of TMD8, which is dependent on the My-T-BCR supercomplex, supporting combinational use of BTK inhibitors and mTOR inhibitors in My-T-BCR supercomplex positive DLBCLs ([@B28]).

Inhibiting the BCL2 Family Members
----------------------------------

The role of BCL2 in DLBCL biology makes it a compelling target for treating DLBCL. Navitoclax (ABT-263), which inhibits both BCL2 and BCL-xL, has shown promising efficacy in B cell malignancies. Nonetheless, the thrombocytopenia caused by inhibiting BCL-xL limits the use of navitoclax. Venetoclax (ABT-199), which is a selective BCL2 inhibitor, has potent antitumor activity but spares platelets. In a phase 1 study which included 34 cases of refractory/relapsed DLBCL, 6 patients achieved objective response with 4 patients achieving CR ([@B119]). There are some clinical trials currently exploring the efficacy of combining venetoclax with other regimens or drugs in refractory/relapsed or newly-diagnosed DLBCL. MCL1 also can be targeted in DLBCL. Knockdown of MCL1 induces cell apoptosis in MCL1-positive DLBCL cell lines ([@B43]). Further, BCL2 inhibition in DLBCL cell lines results in up-regulation of MCL1 expression, possibly interfering with the therapeutic effect of venetoclax ([@B120]). Venetoclax and drugs targeting MCL1 displayed a synergistic effect in inducing apoptosis in preclinical models of high-risk DLBCL ([@B120]). A highly potent and selective inhibitor of MCL1, S63845 (MIK665), has shown significant anti-tumor activity in several DLBCL cell lines and Eμ-Myc lymphoma cells transplanted mouse models ([@B121]). One clinical trial (NCT02992483) is currently investigating the preliminary activity of S63845 in refractory/relapsed multiple myeloma or lymphoma including MYC positive DLBCL. Additionally, the pan-BCL2 inhibitor, obatoclax, which inhibits BCL2, BCL-xL, and MCL1, induces apoptotic cell death in DLBCL cell lines including MCL1 positive ones ([@B43], [@B122]).

Targeting Aberrant p53 Pathway
------------------------------

Targeting an aberrant p53 pathway could be used potentially to restore the function of p53 and trigger cell death. One low-molecular-weight compound, APR-246, is capable of restoring the transcriptional activation function of mutant p53, thus inducing apoptosis in human cancer cells ([@B123]). The safety and activity of APR-246 has been tested in refractory/relapsed hematological malignancies including 3 non-Hodgkin lymphoma cases in a phase 1 clinical trial ([@B124]). In some patients, tumor cells exhibited upregulation of p53 targeted genes and increase apoptosis. Nonetheless, the efficacy of APR-246 in DLBCL remains to be determined. Disrupting the p53-MDM2 interaction impairs MDM2-mediated p53 degradation, thereby increasing p53 stability and expression. Nutlin-3a disrupts the p53-MDM2 interaction and activates p53, thereby up-regulating the pro-apoptotic proteins BAX and PUMA and inducing apoptosis in DLBCL cell lines with t(14;18)(q32;q21) ([@B125]). Idasanutlin, a potent and selective MDM2 antagonist, when combined with obinutuzumab and venetoclax, showed significant antitumor activity in a xenograft model of DLBCL ([@B126]). This three-drug combination remarkably improved the tumor-free survival of mice. Idasanutlin in combination with rituximab and venetoclax is currently investigated in refractory/relapsed DLBCL patients (NCT03135262). One MDM4 inhibitor, XI-011, induced apoptosis in breast cancer cells by activating p53 ([@B127]). The efficacy of MDM4 inhibitors remains to be determined in DLBCL cells. The transcriptional activation activity of p53 depends on its nuclear localization. XPO1 mediates the nuclear export of proteins including p53. Selinexor, an inhibitor of XPO1, inhibits the nuclear export of p53 and restores p53 nuclear localization ([@B128]). In a phase 1 trial, 13 of 41 DLBCL patients treated with single agent selinexor had an objective response, with 4 CR ([@B128]).

Strategies for Using Novel Drugs to Target Cell Death Pathway in DLBCL
----------------------------------------------------------------------

Combination of novel drugs can improve therapeutic effects thorough additive effects or synergistic effects. By using a high-throughput platform to test compounds, Mathews et al. found that ibrutinib was able to cooperate with other drugs including inhibitors of PI3K pathway (agents targeting the PI3K catalytic subunit, AKT, and the mTORC1 complex), BCL2 inhibitors, and cytotoxic chemotherapeutic drugs in killing ABC DLBCL cells ([@B129]). This provides a rationale for use of combination of ibrutinib and other drugs. Furthermore, ibrutinib-resistant TMD8 cells (ABC DLBCL) had elevated BCL2 expression and were vulnerable to BCL2 inhibition; samples from ABC DLBCL patients who had poorer responses to ibrutinib also exhibited higher BCL2 expression ([@B130]). These findings support the combination of ibrutinib and BCL2 inhibitors in the treatment of ABC DLBCL ([@B130]).

The prior treatments, age and performance status need to be taken into consideration when using novel drugs in the treatment of relapsed/refractory DLBCL. It needs to be pointed out that, the ORR is low in relapsed/refractory DLBCL treated with novel drug monotherapies ([@B97], [@B119]). Even for patients who have achieved responses, the responses are not durable. In relapsed/refractory DLBCL patients receiving single-agent ibrutinib, the median response duration was only 4.83 months in ABC DLBCL, where ibrutinib shows significantly better activity, although patients achieving CR had a relatively long remission ([@B97]). Several strategies could possibly be used to apply novel agents in the treatment of DLBCL. In relapsed/refractory DLBCL, combining novel drugs or combining novel drugs with conventional salvage immunochemotherapies could be used to produce higher response rates; for instance, in a phase 1 trial, in 20 patients receiving ibrutinib in combination with R-ICE, 18 patients had a response, with 11 achieving CR ([@B99]). In this setting, autologous stem cell transplantation could be used as consolidation therapy in responding patients who are eligible for autologous stem cell transplantation. In the phase 1 trial of venetoclax in relapsed/refractory DLBCL, one DLBCL patient, who proceeded to allogeneic stem cell transplantation (SCT) after achieving CR with venetoclax, achieved durable remission ([@B119]). This suggests allogeneic SCT could possibly be used to as a consolidative treatment for patients who have achieved remission with novel drugs. More importantly, the chimeric antigen receptor (CAR) T-cell therapy produced significantly higher CR rates and durable remissions in relapsed/refractory DLBCL ([@B131], [@B132]). Therefore, these novel drugs could be used as bridging therapies to the CAR T-cell therapy or in combination with the CAR T-cell therapy. Additional efforts have been made to improve the outcome of DLBCL patients by incorporating novel drugs into R-CHOP induction in the first-line setting ([Table 2](#T2){ref-type="table"}). A recent study showed that the addition of ibrutinib to R-CHOP significantly improved the outcome of non-GCB DLBCL patients younger than 65 years ([@B133]).

Conclusion {#s4}
==========

Cell survival dysregulation represents a hallmark of DLBCL. Disruptions of multiple cellular pathways, including BCR signaling, the BCL2 pathway, the p53 pathway and so on, contribute to dysregulated cell survival in DLBCL. Tumor microenvironment dysfunction as well as EBV infection are also involved in promoting the survival of DLBCL cells. Several novel drugs that are capable of targeting abnormal cell survival pathways have been developed and show promising efficacy in DLBCL preclinical models and patients trials. However, until now, of the drugs discussed above, ibrutinib is the only one that has shown clinical benefit in both relapsed/refractory and untreated DLBCL patients (ABC/non-GCB subtype) ([@B97], [@B133]). The success of ibrutinib suggests that ABC cases, especially those with My-T-BCR supercomplex expression, are highly dependent on the BCR signaling ([@B28]). This also highlights the importance of BTK molecule in the biology of these DLBCL cases. The failure of some drugs in clinical trials could be attributed to, but not to restricted to the following reasons. DLBCL is a heterogeneous disease ([@B16]), different cases may depend on different pathways for cell survival; therefore, when a drug is tested in a group of DLBCL cases, only some of them achieve a response, highlighting the importance of identifying reliable predictors of response. Some cases can rapidly develop resistance mechanisms to a novel drug. Understanding these resistance mechanisms is helpful for developing novel strategies in the treatment of DLBCL. Further understanding of cell survival dysregulation in DLBCL will help to identify more potential targets to provide novel therapeutic options for DLBCL patients in the future.
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